S&P Futures
4,562.50 +3.25 (+0.07%) Dow Futures
35,575.00 +87.00 (+0.25%) Nasdaq Futures
16,048.25 +24.50 (+0.15%) Russell 2000 Futures
1,805.70 -0.10 (-0.01%) Crude Oil
77.60 -0.26 (-0.33%) Gold
2,066.00 -1.10 (-0.05%)
Aclaris Therapeutics, Inc. (ACRS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.8904 |
| Open | 0.9320 |
| Bid | 0.8611 x 900 |
| Ask | 0.8800 x 1200 |
| Day's Range | 0.8618 - 0.9782 |
| 52 Week Range | 0.5900 - 18.5400 |
| Volume | |
| Avg. Volume | 3,829,600 |
| Market Cap | 62.208M |
| Beta (5Y Monthly) | 0.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6600 |
| Earnings Date | Feb 21, 2024 - Feb 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.86 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ACRS
Related Research
- Aclaris Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 08/29/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
ZacksDown -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksAclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
GlobeNewswireAclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (A
